Trending...
- Statement from Dr. Gregory A. Thomas, Republican Candidate for Governor
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
- Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - ColoradoDesk -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on Colorado Desk
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on Colorado Desk
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on Colorado Desk
- Revenue Optics Ignites AI Revolution in Industrial Distribution
- Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development
- Axiros North America Announces New CEO: Gabriel Davidov
- CCHR Exposes Harms Behind Today's Mental Health Awareness Campaigns
- Experience the Innovation of Invisalign Clear Aligners at Apple Grove Dental
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on Colorado Desk
- Now Is the Right Time: Kaltra Highlights Its Proven Replacement Microchannel Coils
- Thomas Family Ranch Donates Thousands Of Pounds Of Meat To Colorado First Movement
- How to Optimize Your Website for AI Search with DeepRank AI
- New Free Science Bingo Cards Help Grade 1 Students Learn Through Play
- DeployHub Joins Catalyst Campus SDA TAP Lab
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on Colorado Desk
- Stone and Leaf Landscaping Launches New Boulder Hardscaping and Fencing Page
- $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Year-Round Deals for Customers With Square Signs
- Statement from Dr. Gregory A. Thomas, Republican Candidate for Governor
- SecurePII Raises US$3.5M (A$5M) to Unlock AI and Compliance for Voice Data and Expands Global Presence
- PH7 Technologies Wins Colorado Cleantech's 9th Annual Mining Cleantech Challenge
- Peter Coe Verbica Stands with Rural Families and Horse Owners: "Keep Horses Classified as Livestock"
- Lt. Governor Dianne Primavera and Major General Robert Davis Visit Colorado's First CONG/AmeriCorps Wildfire Mitigation Crew
- The Mobile-First Company Raises $12M to Build Simple, Powerful Software for Small Teams
- Lick Pineapple Flavored Massage Oil Outperforming and Enticing
- Colorado Springs: City to celebrate completion of Duck Lake restoration project Thursday in Monument Valley Park
- Colorado Springs City Council Affirms Support for Home Rule Authority in Legal Challenge Against State Housing Mandates
- Cerberus ODC in Collaboration with NVIDIA Launches All-American AI-RAN Stack, Enabling AI-Native 5G Today and Accelerating the Path to 6G
- National Compliance Firm issues Artificial Intelligence Policy Program for Mortgage Banking
- Colorado Steps Up to Support Families: Polis-Primavera Administration Thanks JBC for Approval of Emergency Funding For Food & WIC Access Amid Federal Shutdown
- Malibu Jack's Indoor Theme Park will open on November 3rd in Thornton, CO at Thornton Towne Center
- Pastor Darrell Armstrong Suspends Gubernatorial Campaign And Endorses Mikie Sherrill
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
- Colorado: Governor Polis Partners with Governors in Urging White House to Stop Disruption to SNAP, Prevent Hunger for Millions of American Families
- Offline Asset Protection: NJTRX Implements 98 Percent Cold Storage as Industry Faces 2 Billion USD Losses